Sorrento’s and Yuhan’s Joint Venture, ImmuneOncia, receives Approval to begin clinical trial of Anti-PD-L1

Yuhan (KRX:000100.KS) and Sorrento Therapeutics (Nasdaq:SRNE) announce that the South Korean Ministry of Food and Drug Safety has approved ImmuneOncia Therapeutics’ (51% Yuhan/49% Sorrento joint venture formed in March 2016) IND for the initiation of clinical trials for Sorrento-discovered anti-PD-L1 monoclonal antibody STI-A1015 (IMC-001), which is exclusively licensed to ImmuneOncia for select regional markets by Sorrento.

As quoted in the press release:

“We are proud to announce the acceptance of the IND by MFDS for our anti-PD-L1 antibody IMC-001. Throughout the IND-enabling activities, our team has worked collaboratively with our Sorrento colleagues to generate a high-quality submission package that was very well received by MFDS”, said Dr. Kwang Ho Cheong, CEO of ImmuneOncia Therapeutics.

Click here to read the full press release.